(Q38075787)

28 August 2017

1 reference

title

Rituximab therapy in nephrotic syndrome: implications for patients' management (English)

1 reference

28 August 2017

1 reference

1 reference

Aditi Sinha

1

1 reference

28 August 2017

Arvind Bagga

series ordinal

2

1 reference

28 August 2017

language of work or name

English

0 references

publication date

22 January 2013

1 reference

Nature Reviews Nephrology

28 August 2017

published in

1 reference

28 August 2017

volume

9

1 reference

28 August 2017

issue

3

1 reference

28 August 2017

page(s)

154-169

1 reference

Understanding rituximab function and resistance: implications for tailored therapy.

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab in immunologic glomerular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab and minimal change nephrotic syndrome: a therapeutic option

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

The biology of CD20 and its potential as a target for mAb therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

From the bench to the bedside: ways to improve rituximab efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Tissue-type plasminogen activator promotes murine myofibroblast activation through LDL receptor-related protein 1-mediated integrin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

T regulatory cell function in idiopathic minimal lesion nephrotic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Induction of T regulatory cells attenuates idiopathic nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

The prevalence of Th17 cells and FOXP3 regulate T cells (Treg) in children with primary nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Minimal change disease: a “two-hit” podocyte immune disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab therapy in idiopathic membranous nephropathy: a 2-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Nef interaction with actin compromises human podocyte actin cytoskeletal integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab treatment of idiopathic membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Pharmacokinetic Behavior of Rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Efficacy and Safety of Treatment with Rituximab for Difficult Steroid-Resistant and -Dependent Nephrotic Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab in refractory nephrotic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab treatment for adults with refractory nephrotic syndrome: a single-center experience and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab in children with resistant idiopathic nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab for refractory focal segmental glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Posttransplant recurrence of primary glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Recurrence of focal segmental glomerulosclerosis in renal allograft: an in-depth review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Risk factors and outcome of focal and segmental glomerulosclerosis recurrence in adult renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Combination treatment with plasmapheresis and rituximab for recurrent focal segmental glomerulosclerosis after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Minimizing steroid use in pediatric kidney recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Diagnosis and natural course of membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Membranous nephropathy: recent travels and new roads ahead

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Have we changed the outcome in membranous nephropathy? A propensity study on the role of immunosuppressive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Anti-phospholipase A₂ receptor antibodies correlate with clinical status in idiopathic membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab treatment for membranous nephropathy: a French clinical and serological retrospective study of 28 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab therapy for membranous nephropathy: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab in idiopathic membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

The pathology and clinical features of early recurrent membranous glomerulonephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Severe ulcerative colitis after rituximab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Review of the safety and feasibility of rapid infusion of rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab for post-transplant recurrences of FSGS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Current trends in management of hepatitis B virus reactivation in the biologic therapy era

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Fatal interstitial pneumonitis related to rituximab-containing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Non-infectious pulmonary toxicity of rituximab: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Fatal pulmonary fibrosis after rituximab administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Inhibitory human antichimeric antibodies to rituximab in a patient with pemphigus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

New Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoid Malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab for idiopathic membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Efficacy and Safety of Rituximab Second-Line Therapy for Membranous Nephropathy: A Prospective, Matched-Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab for Idiopathic Membranous Nephropathy: Who Can Benefit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab for childhood refractory nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

The factors that may predict response to rituximab therapy in recurrent focal segmental glomerulosclerosis: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab in membranous nephropathy: is it a first-line treatment?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Chapter 2: General principles in the management of glomerular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Idiopathic membranous nephropathy: definition and relevance of a partial remission

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

A glomerular permeability factor produced by human T cell hybridomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Th17/Treg imbalance in adult patients with minimal change nephrotic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab efficiency in children with steroid-dependent nephrotic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood--follow-up after CD19 recovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab in adult patients with immunosuppressive-dependent minimal change disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Chapter 3: Steroid-sensitive nephrotic syndrome in children

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Non-corticosteroid treatment for nephrotic syndrome in children

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Effect of single-dose rituximab on primary glomerular diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab treatment for adult patients with focal segmental glomerulosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

The 45th Annual Meeting on September 6th – 8th 2012, Krakow, Poland

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Short-term efficacy of rituximab versus tacrolimus in steroid-dependent nephrotic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab in patients with the steroid-resistant nephrotic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Successful use of single-dose rituximab for the maintenance of remission in a patient with steroid-resistant nephrotic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab for refractory cases of childhood nephrotic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Loss of living donor renal allograft survival advantage in children with focal segmental glomerulosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Renal allograft survival in transplant recipients with focal segmental glomerulosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Recurrence of focal segmental glomerular sclerosis (FSGS) after renal transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Protocol biopsies for focal segmental glomerulosclerosis treated with plasma exchange and rituximab in a renal transplant patient

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab in post-transplant pediatric recurrent focal segmental glomerulosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Case report: successful treatment of recurrent focal segmental glomerulosclerosis with a novel rituximab regimen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Abrogation of nephrotic proteinuria by rituximab treatment in a renal transplant patient with relapsed focal segmental glomerulosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab therapy prevents focal and segmental glomerulosclerosis recurrence after a second renal transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Pretransplantation combined therapy with plasmapheresis and rituximab in a second living-related kidney transplant pediatric recipient with a very high risk for focal segmental glomerulosclerosis recurrence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Etiology and clinical characteristics of membranous nephropathy in Chinese patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Chapter 7: Idiopathic membranous nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

PLA2R Autoantibodies and Recurrent Membranous Nephropathy after Transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

An immunofluorescence test for phospholipase-A₂-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Use of Rituximab in Focal Glomerulosclerosis Relapses After Renal Transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Treatment of focal segmental glomerular sclerosis with rituximab: 2 case reports

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab administration and reactivation of HBV.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Investigation of polyomaviruses replication in pediatric patients with nephropathy receiving rituximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab-induced bronchiolitis obliterans organizing pneumonia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2012.289

Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells

31 March 2020

1 reference

12 December 2020

Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome

1 reference

12 December 2020

Failure of regulation results in an amplified oxidation burst by neutrophils in children with primary nephrotic syndrome

1 reference

12 December 2020

Pharmacovigilance and PML in the oncology setting

1 reference

12 December 2020

Long-term effect of rituximab in maintaining remission of recurrent and plasmapheresis-dependent nephrotic syndrome post-renal transplantation - case report

1 reference

12 December 2020

Recurrent disease in renal transplants

1 reference

12 December 2020

Recurrent glomerulonephritis in the renal allograft: an update of selected areas

1 reference

12 December 2020

Nephrotic syndrome in children.

1 reference

12 December 2020

Cell type- and stage-specific expression of the CD20/B1 antigen correlates with the activity of a diverged octamer DNA motif present in its promoter

1 reference

12 December 2020

[Change of serum immunoglobulin level in patients with diffuse large B cell lymphoma after rituximab combined with chemotherapy]

1 reference

12 December 2020

Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: report of four cases and review of the literature.

1 reference

12 December 2020

Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children

1 reference

12 December 2020

[Level of Th17 cell and CD4(+);CD25(+); Foxp3(+); regulatory T cell in peripheral blood mononuclear cells of primary nephrotic syndrome in children].

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2012.289

1 reference

Dimensions Publication ID

28 August 2017

1032839688

0 references

1 reference